Investors & Media

Investors & Media

Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity.

Please use the Investor & Media drop down menu to access more tools and information

Merus - Closing In On Cancer
Upcoming Events
Date Title
May 18, 2021 at 8:00 AM EDT

Summary Share Price

Copyright West LLC. Minimum 15 minutes delayed.